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We have developed a multiplex reporter system to monitor multiple biological variables in real-time. The
secreted Gaussia luciferase was fused to ten different epitope tags (Gluctag), each expressed in different
tumor cells. By immunobinding of the tags followed by Gluctag detection, this system allowed the
independent and real-time monitoring of mixed cell cultures in vitro and of mixed subcutaneous and
intracranial tumor subpopulations in vivo.
T
ostudycomplexprocessesinsystemsbiology,toolsareneededthatgiveinsightintomultiplemolecularand
cellular interactions simultaneously and in real-time
1,2. Several cellular reporter systems are in use to shed
lightonbiologicalprocesses, manybasedonluciferaseenzymesandtheirphotonproductionuponluciferin
substrate addition, including Firefly luciferase (Fluc)
3, Renilla luciferase (Rluc)
4, and Gaussia luciferase (Gluc)
5,6.
These bioluminescent reporters have been used to monitor biological processes such as cellular proliferation and
differentiation
7, transcription factor activity
8, translational repression by miRNA
9,10, and intercellular interac-
tions
11, reviewed in
12. Other commonly used reporters are based on the green fluorescent protein (GFP), the red
fluorescent protein (RFP) and, more recently, near infra-red fluorescent proteins
13,14 which can be multiplexed
together to monitor several processes simultaneously using spectral unmixing in conjunction with fluorescence
molecular tomography
15. These reporters have several disadvantages including low sensitivity due to autofluor-
escence, complexity, and the requirement of expensive instrumentation. Further, similar to bioluminescence,
limited numbers of variables can be monitored simultaneously, limiting their use in multiplex screening assays
and cellularheterogeneity studies.Here, wedevelopedamultiplexbioluminescence assaythatallows monitoring
ofmanyvariablesinreal-timewithinthesamebiologicalsystem.ThisassayisbasedonGlucsincethisreporteris
highlysensitive,naturallysecreted,andcanbedetectedintheconditionedmediumofcellsincultureaswellasin
the blood of animals ex vivo, allowing real-time monitoring of cellular variables
5,6.
Results
WeconstructedalibraryoflentiviralvectorsconsistingoftheGluccDNAfusedtotendifferentepitopetagsatits
C-terminus, under the constitutively active cytomegalovirus (CMV) promoter resulting in GlucFlag, GlucHis,
GlucHA,GlucAcV5,GlucV5,GlucGlu,GlucMyc,GlucKt3,GlucAu1,GlucE2,andthecontrolreporterconstructwithout
tag,GlucCtrl.Theselentiviralvectorsalsoexpressceruleanfluorescentprotein(CFP)separatedfromGluctagbyan
internal ribosomal entry site (IRES) element as a marker for transduction efficiency (Fig. 1a and Methods
section). We employed human U87 glioblastoma cells stably expressing Fluc and the mCherry fluorescent
protein
6 (U87-FM) for validation of the Gluctag multiplex system. These cells were transduced with each of
the lentiviral vectors to produce ten different cell lines, each stably expressing a different Gluctag and CFP
(U87-FM-Gluctag-CFP). Fluorescent microscopy analysis for mCherry and CFP showed that these cells were
nearly 100% transduced with the reporter vectors (Fig. 1b). We first demonstrated that all of the individual U87-
FM-Gluctag-CFP cells expressed the corresponding tags by immunostaining using specific antibodies, except for
GlucAu1 that was not detectable by immunostaining attributed to anti-Au1 antibody properties (Fig. 1c). As a
controlwestainedcellsexpressingGlucctrlwiththedifferenttagantibodies,whichdidnotshowanystaining(data
not shown). We confirmed Gluctag expression by Western blot using anti-tag antibodies (Sup. Fig. 1a) and RT-
PCR of the tag region (Sup. Fig. 1b and c). Next, we determined the effect of the tags on Gluc by measuring
luciferase activity at different time points in an aliquot of conditioned medium from U87-FM cells expressing
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SCIENTIFIC REPORTS | 3 : 1046 | DOI: 10.1038/srep01046 1Figure 1 | Gluctag multiplex assay development and validation in vitro. (a) Schematic of the lentiviral vector constructs encoding the luciferase reporters.
(b) Fluorescence microscopy analysis of a representative U87-FM-Gluctag-CFP cells (using GlucFlag reporter) showing mCherry levels (in red; marker for tumor
cells) and CFP expression (in blue; marker for transduction efficiency). (c) Immunostaining against the various tags in U87-FM cells expressing differentGluctag.
(d) Gluc activity in U87 cells expressing different Gluctag with respect to cell proliferation over time and cell number. The dashed line represents GlucCtrl activity.
(e) Gluctag immunobinding assay versus total Gluc activity using serial dilutions of the conditioned medium from a 1-day culture of U87-FM cell lines
expressing the individual Gluctag reporters. (f-g) Equal mixture of ten cell lines each expressing a different Gluctag reporter. (f) Immunobinding assay of Gluctag
from a mixed population. (g) Immunostaining for the ten different tags expression in the mixed population of U87-FM cell culture. (h-i) U87-FM cells
expressing all ten different Gluctag reporters. (h) Immunostaining for the ten different tags in one cell line. The insert panels show staining of control parental
cells. Percentages of positively stained cells are indicated. (i) Immunobinding assay of all ten Gluctag reporters in one cell line after TMZ treatment (black bars)
compared to untreated control (white bars). (j) CFP fluorescence microscopy of cells in (h–i) with or without 600 mM TMZ. Size bar (in b,c, g and h) 5
200 mm. Size bar (i) 5 400 mm. N.d. 5 not detectable.
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azine. We demonstrated that fusion of epitope tags to Gluc does not
dramatically affect the expression, secretion or activity of Gluc
(Fig. 1d and supplemental Fig. 1a–c). We then used the conditioned
media containing the different Gluctag constructs to optimize anti-
body-tag immunobinding in a 96-well plate format (Methods).
Plates were first coated with monoclonal antibodies against the dif-
ferent tags and incubated with different amounts of conditioned
medium allowing Gluctag immunobinding. Subsequently, the wells
were washed to remove unbound Gluctag and subjected to the Gluc
assay by direct addition of coelenterazine to the wells and measuring
photon counts using a plate luminometer. As a control, an aliquot of
Figure 2 | Gluctag multiplex assay in vivo. (a)U87-FM cells expressingdifferent Gluctagwere implanted subcutaneously innude mice (n53)andtumor
growth was monitored overtime. Shown are representative Fluc bioluminescence images of the U87-FM-Gluctag-CFP tumors expressing the GlucFlag
reporter. (b), Quantitation of the different U87-FM tumors expressing different Gluctag reporters; Fluc activity (black), calliper measurement (green),
total Gluctag activity in the blood (red), and bound Gluctag activity after immunobinding (blue). (c–d) U87-FM cells expressing the different Gluctag
reporters were mixed in equal amounts and injected subcutaneously in the same mouse (n55). Tumor growth was monitored using Fluc imaging and
total Gluc blood assay as in (a–b). Individual cells subpopulation within the same tumor were monitored using the multiplex Gluctag immunobinding
assay.(e)ImmunostainingforthetendifferenttagsexpressioninthemixedU87-FM-Gluctag-CFPtumor.Blackarrowsindicatepositivestainingforcells
expressingthecorrespondingGluctag.Sizebar5200 mm.N.d.5notdetectable.(f–g)MixedpopulationofU87-FMcellsexpressingalltendifferenttags
wereimplantedintracraniallyinthebrainofnudemice(n55).TumorgrowthwasmonitoredwithFlucimagingandGluctotalbloodassay,anddifferent
tumor cell subpopulations were monitored using the multiplex Gluctag assay as in (c–d). Fluc bioluminescence imaging of a representative mouse is
shownin(f).Datashownin(b,d,andg)asaveragerelativelightunits(RLU)6standarddeviation.Heatscalesin(a,candf)indicaterelativephotonlevels
(photons/sec) as measured by the CCD camera.
www.nature.com/scientificreports
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determined that six of the ten individual Gluctag constructs, i.e.
GlucFlag, GlucHis, GlucHA, GlucAcV5, GlucV5, GlucGlu, reported with
high-efficiencyafterimmunobindingintheantibody-coatedwells,as
compared to total Gluctag activity (Fig. 1e). The GlucMyc, GlucKt3,
GlucAu1, and GlucE2 reporters showed lower activity upon immuno-
binding,attributedtosuboptimalantibody-taginteractions. Inorder
to demonstrate the use of the Gluctag system for multiplex applica-
tions, wemixed equal numbers of the ten different U87-FM-Gluctag-
CFP cells and plated them in a single well. One, three and five days
later, we measured the total Gluc level in aliquots of the conditioned
medium. The levels of the individual Gluctag reporters in the mixed
culturemediumwereanalyzedbyimmunobindingwiththedifferent
tag specific antibodies. We were able to monitor in real-time the
growth of the individual U87-FM-Gluctag-CFP cell populations in
the mixed culture (Fig. 1f). Immunostaining confirmed the express-
ion of each tag in the corresponding cells in the mixed culture, again
except for GlucAu1 (Fig. 1g). In order to determine whether we can
measure the activity of ten different Gluctag constructs in the same
cell, we transduced U87-FM cells with all ten different lentiviral
gluctag reporters. Immunostaining of the U87-FM-Gluc103 tagCFP
glioblastoma cells with tag specific antibodies showed that almost all
cells expressed all ten different Gluctag constructs (Fig. 1h). The tag
expression as demonstrated by immunostaining is less intens in
Fig.1hascomparedtoFig.1c,whichweattributetothetransduction
pool of ten different lentivectors used in Fig. 1h. We used these cells
to monitor cell viability in the presence and absence of the alkylating
agent temozolomide (TMZ), the standard chemotherapy for glio-
blastoma patients. Gluctag immunobinding assays were used to
determine the expression of all ten reporters in the presence or
absence of TMZ. We treated the U87-FM-Gluc10 3 tagCFP cells with
TMZ and measured Gluctag activity after six days (Fig. 1i).
Precipitation of all ten different Gluctag reporters showed a ,75%
decrease in Gluc bioluminescence signal after TMZ treatment, sim-
ilar to the total Gluc signal and confirmed by CFP immunofluores-
cenceanalysis(Fig. 1j).Altogether, theseresultsdemonstrate thatwe
can measure biologically relevant differences using our multiplex
Gluctag system.
In order to determine the in vivo applicability of the Gluctag
reporter assay, we injected the ten individual U87-FM cell cultures
expressing either one of the Gluctag or GlucCtrl reporters subcuta-
neously in nude mice for singleplex application. In another set, we
injectedmicewithPBSasanegativecontrol(12groups;n53/group).
Tumor growth was monitored over time by calliper measurement,
and Fluc bioluminescence imaging (Fig. 2a,b). Blood was collected
frommiceatdifferenttimepointsand5 mlofwholeblood(optimum
amountforGlucbloodassay
16)wasassayedfortotalGlucactivity.At
the same time, 25 ml of blood was analyzed for Gluc activity after
immunobinding on wells coated with the corresponding tag anti-
body (Fig. 2b). All of the Gluctag reporters, except GlucE2, allowed
blood monitoring of tumor growth over time in a singleplex assay.
We compared the tumor growth as measured by calliper, Fluc
imaging and Gluc blood assay to signals obtained from the ten dif-
ferent Gluctag reporters after immunobinding (Fig. 2b). The six
Gluctag reporters GlucFlag, GlucHis, GlucHA, GlucAcV5, GlucV5,
GlucGlu were more sensitive in detecting tumor growth than the
others, possibly due to a higher affinity of the antibodies to these
tags. To demonstrate the use of the Gluctag system for multiplex
applications, we mixed equal numbers of U87-FM cells expressing
the ten different Gluctag and implanted the heterogeneous cell pool
subcutaneously in nude mice (n55). We monitored tumor growth
by Fluc bioluminescence imaging and total Gluc blood assay
(Fig. 2c,d). Importantly, we were able to efficiently monitor the
growth of the individual subpopulation of the U87-FM cells expres-
sing the different high-efficiency Gluctag reporters (GlucFlag, GlucHis,
GlucHA, GlucAcV5, GlucV5, GlucGlu) in the same tumor over time
(Fig. 2d). We confirmed the expression of all tags (except for
GlucAu1) in the same tumor by immunostaining (Fig. 2e). To deter-
minetheapplicabilityoftheGluctagmultiplexsystemindeeptissues,
the mixture of the ten different U87-FM-Gluctag-CFP cells were
implanted orthotopically in the brain of nude mice (n55). We mon-
itoredtumorgrowthbyFlucbioluminescenceimagingandtotalGluc
blood assay (Fig. 2f,g). Again, we were able to monitor the intracra-
nialgrowthoftheindividualsubpopulationsofU87-FMcellsexpres-
sing the high-efficiency Gluctag reporters within the same brain
tumor in real-time, by blood sampling and the application of the
Gluctag multiplex reporter system (Fig. 2g).
Discussion
Here we demonstrated the functionality of the Gluctag multiplex
reporter system by the parallel monitoring of mixed cell cultures in
vitro, and of subpopulations in mixed subcutaneous and intracranial
tumorsexvivo.Theindividualepitopetagscouldalsobeemployedto
localize expression by immunostaining. We used ten different
Gluctagreporters,butthistaglibrarycanbereadilyextendedallowing
for increased multiplexing. In addition, antibody binding of the low-
efficiency tags in the Gluctag immunobinding assay might be further
optimized to achieve higher sensitivity since these tags, except for
GlucAU1, were efficiently detected by immunostaining. Real-time
monitoringofindividualcellsinaheterogeneousmixturemayallow,
for instance, multiplexed RNAi screening or measurement of drug
responses of multiple cell populations in parallel. The Gluctag multi-
plex system might be extended to monitor different variables in a
single cell type. For instance, engineering each individual Gluctag
under the control of different transcription response elements for
multiplex transcription factor activity measurements
7, constructing
microRNA (miRNA)-binding sequences in the 39-UTR of the
Gluctag constructs for multiplex monitoring of miRNA activity
10 or
by inserting different protease cleavage sites into the Gluctag gene for
multiplex protease activity measurement
17. This reporter assay pro-
vides a versatile tool to study complex processes with different vari-
ables in systems biology.
Methods
Cells.Forinvitroandinvivovalidation,weusedtheglioblastomacelllineU87,stably
co-expressing Firefly luciferase and mCherry fluorescent protein. Cell lines were
maintained in DMEM high glucose complemented with sodium pyruvate, stable
glutamine, 10% FBS and pen/strep (all PAA), incubated under standard cell culture
conditions of 37uC and 5% CO2.
Lentivirus vector construction and transduction. First, we amplified Gluc by PCR
using Accuprime Pfx DNA polymerase (Life Technologies) from CSCW-Gluc-IRES-
CFP
6 with specific primers that incorporate an XbaI site downstream of the Gluc
cDNA (Forward primer: 59- GCGTGTACGGTGGGAGGTCT-39, reverse primer:
59-TCTCGAGTAGAGATCTGTCACCACCGGCCCCCTT-39). The reverse primer
also covers the original stop-codon that is thereby removed. The Gluc cDNA, now
containing a unique XbaI site, was ligated back into the CSCW-Gluc-IRES-CFP
vector with T4 DNA ligase (Life Technologies), after removal of the wild-type Gluc
using NheI and XhoI (Life Technologies). Plasmid DNA was transformed in XL-10
Gold ultracompetent cells (Agilent Technologies), cultured overnight in LB agar
containing 50 mg/ml Ampicillin. We isolated DNA using a DNA plasmid mini kit
(Qiagen) and verified successful transformation by XbaI restriction analysis. The
Gluc construct was then digested with XbaI and XhoI to insert the different epitope
tags. The epitope tags were designed with an XbaI site upstream, a stop codon and
XhoI site downstream. A total of 20 mM of both single strand oligonucleotides of the
acquired tag DNA (Life Technologies, see Table S1 for sequences) was annealed in
annealing buffer (100 mM Tris-HCl pH 7.5, 1 M NaCl and 10 mM EDTA) by
heating to 65uC for 10 minutes and slow cooling to room temperature. The epitope
tag was then inserted into the vector using T4 DNA ligase and transformed in XL-10
Goldultracompetentcells.BacteriawereculturedandDNAwasisolated. Weverified
theGluctagconstructsbysequencingusingBigDyeTerminatorv3.1CycleSequencing
kit (Life Technologies, primer: 59-GCCAACGTGCAGTGTTC-39). The Gluctag
construct was co-transfected with a third generation lentiviral packaging mix
(pMDLg/pRRE, pRSV-Rev and pMD2.G, Addgene) in HEK293T cells using
Lipofectamine2000(LifeTechnologies).Viruswasharvestedtwoandthreedaysafter
transfection and cell debris was spun down for five minutes at 1,000 3 g. U87 cells
were transduced overnight with lentivirus using a multiplicity of infection of 100
transducing units per cell in the presence of 8 mg/ml polybrene in standard culture
conditions.
www.nature.com/scientificreports
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(co-expressed with the Gluctag construct) and mCherry fluorescent protein (co-
expressed with Fluc) using fluorescent microscopy (Leica).
Immunostaining and antibodies. For in vitro immunostaining, cells were fixed in
3.7% formaldehyde for 20 minutes, washed with PBS and permeabilized with PBS
containing 0.1% Triton X-100. Cells were then washed three times in PBS containing
5% FBS and blocked with PBS containing 5% FBS. Primary mouse-anti-tag
monoclonalantibody(10 mg/mlin100 mlofPBS,TableS1)wasaddedandincubated
foronehouratroomtemperature.Cellswerewashedagainandincubatedwith15100
goat-anti-mousehorseradishperoxidase(HRP)conjugate(Dako)foronehour.After
washing, cells were stained with DAB1 (Life Technologies). For mouse tissue
staining, tumors were removed and embedded in paraffin. Microtome sections of 5
micron on glass slides were deparaffinized in xylene and rehydrated in ethanol series
of100%,96%,and70%ethanol.Endogenousperoxidewasblockedwith0.3%H2O2in
methanolfor30minutes.Afterrinsingwithwater,antigenswereretrievedwithcitrate
buffer(pH 6)with 0.05%Tween 20 using amicrowave(Bosch, fiveminutes 900watt,
10 minutes 360 watt). After slowly cooling, tissues were washed three times with PBS
and incubated with primary antibody (10 mg/ml), for one hour at room temperature.
After washing three times again, tissues were incubated with REAL Envision Rabbit
anti-mouse (Dako and REAL DAB1 stained (Dako). Tissue sections were
dehydrated with ethanol series as before and fixed in xylene. Cells and sections were
imaged and photographed by light microscopy (Leica).
Western blot. U87-FM-Gluctag-CFP cells were lysed in RIPA buffer and mixed with
Laemli buffer containing b-mecaptoethanol (80 ml/ml). The samples were separated
using a 10% SDS-PAGE gel and the XCell-II blot module (Invitrogen). Primary
antibodies (Table S1) were used in a 153,000 dilutions and goat-anti-mouse HRP
immunoglobuline (Dako) secondary antibody was used in a 152,000 dilution.
Incubation times were 1 hour at room temperature.
RT-PCR. U87-FM-Gluctag-CFP RNA was isolated using Trizol (Invitrogen)
according to manufacturer’s guidelines. cDNA was generated using Omniscript RT
kit (Qiagen) and PCR was performed in triplo using FastStart SYBR Green Master
(Rox) mix (Roche). As a forward primer we used 59- GCCAACGTGCAGTGTTC-‘3,
which is located in the Gluc gene. We used the tag antisense oligonucleotides as tag
specific reverse primers (Table S1).
In vitro gluc activity assay. For Gluctag activity measurement over time, 50,000 cells
were plated in a 24-well plate and incubated overnight. A total of 10 ml conditioned
medium was harvested from cells and Gluc activity was measured by adding 50 ml
(5 mg/ml) coelenterazine (Nanolight Technologies) in PBS and 0.1% Triton X-100).
Beforeadditiontothesample,thesubstratewasincubatedatroomtemperaturefor30
minutes for stabilization. Photon counts were determined over 10 seconds in a
luminometer (Berthold Technologies). For the measurement of Gluctag activity with
respect to cell number, indicated numbers of cells were plated in a 24-well plate and
incubated overnight. Gluctag activity in medium was determined as described above.
Gluctag immunobinding assay. White goat-anti-mouse-coated 96-well plates
(Thermo Scientific) were washed three times with PBS containing 0.05% Tween 20
and incubated with 50 ml (10 mg/ml) of each of the mouse monoclonal antibody
directed against the specific epitope tags (Table S1). Incubation time was two hours
whilecentrifugingat5003gat4uC.Wellswerewashedandblockedthreetimeswith
PBScontaining5%FBSand0.05%Tween20onaplateshakerat65–75rpm.Atotalof
30 ml of Gluctag conditioned medium or Gluctag mouse blood was added to the well
and incubated for two hours at room temperature on a microplate shaker at 65–75
rpm.Wells werewashedfive timesforfive minutesona plateshaker at65–75rpm. A
total of 50 ml Gluc substrate (5 mg/ml coelenterazine in PBS and 0.1% Triton X-100)
was added to the well and photon counts were determined in a microplate
luminometer(Tecan)at0.1secondperwell.ForthecomparisonoftheboundGlucto
the total Gluc activity, aliquots of conditioned medium or 5 ml mouse blood were
transferred to a white 96-wells microplate and assayed using 50 ml( 5mg/ml)
coelenterazine in PBS and 0.1% Triton X-100.
In vivo experiments. All in vivo experiments were subject to ethical committee
approval and are in accordance with VU University Medical Center and national
regulations. For subcutaneous tumor xenograft model, six weeks old athymic Nude-
Foxn1
nu mice (Harlan) were implanted with 5 3 10
5 U87-FM-Gluctag-CFP cells in
50 ml DMEM and 50 ml Matrigel (BD Biosciences). For intracranial tumor
implantation, a stereotactic frame (Harvard Biosciences) was used to inject cells
verticallyintotherighthemisphere.Generalanesthesiawasinducedbysubcutaneous
injection of buprenorphine hydrochloride (0.1 mg/kg). The mice were further
anesthetized with oxygen containing 2.5% isofluorane. After skin incision, lidocaine
drops (5 mg/ml in PBS) were administered topically. A small drill was used to drill a
holeintotheskull. Coordinates usedforinjectionwereX50.5 mm,Y52 mm,Z5
22 mm from the bregma. A total of 2 3 10
5 cells in 5 ml of DMEM was injected
vertically.Onindicateddaysafterinjection,tumorsizewasmonitoredusingacalliper
(forsubcutaneous)andbioluminescenceinvivoFlucimaging,byinjecting D-luciferin
(100 mg/kg) intraperitoneally. Imaging was performed with an IVIS CCD camera
and analyzed withLiving Image software(Caliper Life Sciences). Wecollected 300 ml
mouse blood aliquots from the tail vein in Microvette CB300 EDTA capillary tubes
(Sarstedt) for ex vivo whole Gluc measurements and Gluc immunobinding assays.
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